T1D Exchange Announces 13 Real-World Data Presentations and Posters at the American Diabetes Association (ADA) 85th Scientific Sessions
Studies underscore advances in screening, mental health, health equity, and early intervention in diabetes care.
New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like peptide-1 (GLP-1) therapy.
Company strengthens leadership in type 1 diabetes (T1D) and T2D research, with more than 100 publications since 2020.
BOSTON, June 11, 2025 /PRNewswire/ -- T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 diabetes (T1D) and type 2 diabetes (T2D), today announced that new research using real-world data from its Quality Improvement Collaborative (T1DX-QI) and online patient Registry will be shared during 13 presentations at the American Diabetes Association (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.
The studies highlight emerging trends and outcomes in diabetes care, including efforts to improve screening for T1D autoantibodies, technology usage, particularly CGMs, and the increased use of GLP-1 therapies by individuals with T2D. Drawing on data from the organization's Registry of more than 20,000 people with T1D, several presentations offer insights into clinical outcomes as well as the broader impact of the disease, including financial strain, mental health challenges, and comorbid conditions. A full list of abstracts being presented is available here.
"We are excited to unveil impactful research driven by our growing T1DX-QI network and robust patient Registry," said David Walton, Chief Executive Officer of T1D Exchange. "By uniting over 60 endocrinology clinics, data from 150,000+ individuals with T1D and T2D, and patient-reported outcomes from people with T1D and their caregivers, we're building a collaborative, evidence-driven knowledge base to expand our capabilities, deepen datasets, and generate insights that improve care for people with diabetes."
Key studies include an oral presentation exploring equitable strategies to increase CGM adoption by people with T2D, expanding on prior research in T1D:
276-OR, T1D Exchange Multicenter Study—Increasing CGM Adoption in Type 2 Diabetes on Sunday, June 22, 3:15 - 4:15 p.m. CT in Room W185 A-D
Additionally, data from 12 studies will be presented during the General Poster Sessions on Saturday, June 21, Sunday, June 22, and Monday, June 23, from 12:30 - 1:30 p.m. CT in Poster Hall F1.
"Many of our presentations this year highlight the strength of our engaged T1D community and the value of our growing Registry. Thousands of participants contributed to research that explores the financial, emotional, and clinical realities of living with T1D," said Wendy Wolf, PhD, Vice President of Registry and Outcomes Research at T1D Exchange. "Our Registry not only provides real-world, patient-reported insights, but also serves as a powerful platform for targeted study recruitment, enabling partners to accelerate research that is closely aligned with patient needs. Our Registry has helped recruit for dozens of research studies, including 16 clinical trials – with more than 10,000 Registry participants enrolled in external studies to date."
About the T1DX-QI and the T1D Exchange RegistryThe T1D Exchange Quality Improvement Collaborative (T1DX-QI) brings together 60+ endocrinology clinics across the U.S., collectively treating more than 150,000 people living with type 1 and type 2 diabetes, to identify and address gaps in care and accelerate evidence-based, practical solutions. Participating clinics contribute anonymized patient data and insights from their respective clinics, expanding the collective knowledge base and creating a unified data asset to expedite improvements in care for all people living with type 1 and type 2 diabetes.
The T1D Exchange Registry is an online longitudinal study that tracks disease progress and gathers information directly from people with type 1 diabetes and caregivers of children with type 1 diabetes. To date, the Registry includes over 20,000 participants in the U.S. These individuals share patient-reported outcomes, including data on disease management. Participants update their information annually, participate in internal research projects, and are connected to external curated research opportunities, including clinical trials. The online Registry is designed to lower barriers to participating in diabetes research, including patient populations often underrepresented in clinical studies.
The T1DX-QI and T1D Exchange Registry have contributed to more than 100 publications by T1D Exchange in leading medical journals since 2020.
About T1D ExchangeT1D Exchange is a leader in harnessing data to advance diabetes care and outcomes by driving collaborative change. Through real-world evidence and clinical data collection and analysis, its programs provide novel insights that identify gaps in care and refine best practices to improve the lives of those living with diabetes. T1D Exchange supports quality improvement and innovation through its Quality Improvement Collaborative (T1DX-QI), online patient Registry, and data-oriented research services. Through a knowledge-sharing and collaboration-focused approach, T1D Exchange accelerates real-world impact by providing clinicians, researchers, industry partners, and advocates with the resources and services they need for better decision support and population health management. T1D Exchange is a nonprofit organization established in 2010 with ongoing support from The Leona M. and Harry B. Helmsley Charitable Trust.
To learn more about T1DX-QI member clinics, click here. For more information on the Registry, visit t1dregistry.org.
Media Contact:Suzanne McKeeDirector of Marketing, T1D ExchangePhone: 617-671-0429Email: smcKee@t1dexchange.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/t1d-exchange-announces-13-real-world-data-presentations-and-posters-at-the-american-diabetes-association-ada-85th-scientific-sessions-302478361.html
SOURCE T1D Exchange
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
4 hours ago
- Buzz Feed
Lizzo Talks About Using Ozempic For Weight Loss
There's no point in stressing out over speculation and rumors regarding Lizzo — she's an open book. On a June 19 episode of the Just Trish podcast, Lizzo admitted that she tried Ozempic and other GLP-1 drugs, which are used to regulate type 2 diabetes and obesity, at one point in her "weight release" journey. Over the years, the "Truth Hurts" singer has been rather forthcoming with her fitness journey, documenting it on social media and sharing her progress with her fanbase. "I tried everything," she told Trisha Paytas. "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same item." In the podcast, Lizzo shut down critics of Ozempic and GLP-1 drugs, noting that people are not "cheating" by using the products. "It's not easy," Lizzo said. "It's a drug to help somebody with something they're struggling with. I think people... it's their way of being fat phobic when you're telling someone they're cheating." "They tell people they're cheating by getting that weight loss surgery. I heard about that weight loss surgery. That shit sounds very hard actually. A lot people felt like they almost died on the table, and they got so sick after getting the weight loss surgery. That shits not easy." "I feel like people just like to make fun of fat people. Whether you're big or small or got small, they like to make fun of us," she said. Lizzo claimed that she started noticing different results when adding meat back into her diet. "What did it for me is it was not being vegan," she said. "Because when I was vegan, I was consuming a lot of fake meats, I was eating a lot of bread, I was eating a lot of rice and I had to eat a lot of it to stay full." In her opinion, the "fake sugar and weird shit" in processed foods was holding her back, causing her to eat 3,000 to 5,000 calories a day. "When I started actually eating whole foods and eating, like, beef and chicken and fish," she said, "I was actually full and not expanding my stomach by putting a lot of fake things in there that wasn't actually filling me up." "I feel like I worked really, really hard and I was intentional what I did with my body," she added. And that's that! Take that shame somewhere else because Lizzo doesn't play that. Watch the full episode of Lizzo on the Just Trish podcast here.
Yahoo
5 hours ago
- Yahoo
Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association
CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the presentation of new human clinical data at the 85th Scientific Sessions of the American Diabetes Association (ADA), held in Chicago. The poster, titled 'Uncovering the bidirectional glucose-dependent relationship of insulin and glucagon: a meal-challenge study in patients with Type 1 diabetes,' was presented by Dr. Guillaume Kraft, Research Assistant Professor at Vanderbilt University. The study examined how insulin and glucagon behave when delivered together in a fixed ratio at mealtime in people with Type 1 diabetes. The study builds on earlier preclinical research at Vanderbilt University, where scientists observed that insulin and glucagon might interact differently depending on a person's blood sugar level. In that work, the hormones appeared to shift in dominance—insulin having a stronger effect when glucose was high, and glucagon becoming more influential when glucose was low. This human study explored whether similar patterns could be seen when the two hormones were given together in a single fixed ratio at mealtime to people with Type 1 diabetes, under closely monitored conditions. The clinical trial was led by Dr. Bruce Bode and his team at Atlanta Diabetes Associates involving 15 participants with Type 1 diabetes. The results suggested that combining glucagon with insulin at a single fixed ratio at mealtime may offer protection against hypoglycemia during the post-meal drop in blood sugar—without interfering with key metabolic processes. The combination was well tolerated and showed a favorable safety profile. 'We are grateful to Dr. Kraft and the research team at Vanderbilt, and to Dr. Bode and his team in Atlanta, for advancing this important translational work,' said Dr. David Maggs, co-founder of Abvance Therapeutics. 'This study provides early human insight into how carefully designed glucagon-insulin combinations may offer a new tool for improving the day-to-day safety of intensive insulin therapy.' The results mark the first human data evaluating fixed-ratio co-administration of insulin and glucagon in a mealtime setting and offer early support for Abvance's approach to rationally engineered glucagon analogs. 'Abvance is excited to build on this foundational work as we advance our pipeline of glucagon-based therapies designed to integrate seamlessly into real-world treatment strategies,' added Maggs. About Abvance TherapeuticsAbvance Therapeutics, Inc. is a privately held biotechnology company advancing novel glucagon-based therapies designed to integrate into the lived experience of diabetes care. Founded on research from Vanderbilt University and led by a team with expertise in diabetes therapeutics, drug development, and health technology. For more information visit Media & Investor ContactsEdward Raskined@ Veena Raoveena@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
9 hours ago
- New York Post
5 foods that naturally stimulate the ‘Ozempic hormone' — without drugs
Want to shed pounds without getting poked? Your fork might be the fix. While GLP-1 drugs like Ozempic and Wegovy have taken the weight-loss world by storm, there are some everyday foods that offer similar benefits naturally — no needle required. 'No one food is a magic bullet for anything, but getting a balanced diet rich in nutrition-dense foods is a great way to manage your appetite and feelings of being full,' Dr. Amir Khan, a general practitioner, said in an Instagram video. Advertisement Khan broke down five foods to add to your diet if you're looking to naturally boost your levels of GLP-1, the hunger-controlling hormone that these trendy drugs are designed to mimic. An added bonus: These foods are also packed with nutrients that benefit your whole body, not just your waistline. But first: what is GLP-1? Advertisement GLP-1 is a hormone released by the small intestine after you eat, according to the Cleveland Clinic. It plays several key roles in how the body processes food, including triggering insulin production to turn meals into energy and lower blood sugar levels. 5 About 12% of US adults have tried a GLP-1 drug. millaf – Advertisement It also suppresses glucagon, a hormone that raises blood sugar, and slows stomach emptying, which helps you feel fuller for longer. GLP-1 drugs mimic this natural process by curbing appetite and reducing food intake, often leading to weight loss. But according to Khan, some kitchen staples can produce similar effects. #1 Eggs Packed with protein and monounsaturated fats, eggs have been shown to help boost GLP-1 secretion. Advertisement 'Egg whites in particular are thought to be beneficial to GLP-1 release,' Khan said. 5 Eggs may even help trigger the release of GLP-1 and other satiety hormones. Mara Zemgaliete – A 2016 study compared a bagel breakfast to one with three eggs. The egg meal led to lower blood sugar after eating, less hunger, and reduced food intake over the next 24 hours. #2 Certain nuts Almonds, pistachios, and walnuts may help boost GLP-1 thanks to their fiber, protein, and healthy fats. These nutrients work together to slow digestion, leading to a more steady rise in blood sugar and improving insulin sensitivity. #3 High-fiber grains Grains like oats, barley and whole wheat are packed with soluble fiber, which dissolves in water and forms a gel-like substance in your gut. 5 Soluble fiber, found in oats, barley, and rye, slows down the digestion process. baibaz – Advertisement This gel slows digestion and the release of glucose into your bloodstream, preventing sugar spikes and triggering GLP-1 release. #4 Olive oil 'Studies suggest unsaturated fats, like those in olive oil, stimulate GLP-1 release better than saturated fats found in butter,' Khan explained. Olive oil also slows carbohydrate digestion, helping prevent rapid blood sugar spikes. Advertisement Its polyphenols and vitamin E provide antioxidant and anti-inflammatory benefits that support hormone regulation — including GLP-1. A 2021 review found that a Mediterranean diet rich in olive oil led to higher post-meal GLP-1 levels, improved insulin sensitivity, and lower blood sugar compared to diets high in saturated fats. #5 Some vegetables Veggies like Brussels sprouts, broccoli and carrots are loaded with fiber, which helps regulate blood sugar. Advertisement Gut bacteria break down that fiber into short-chain fatty acids, which Khan says signal gut cells to release GLP-1 into the bloodstream. 5 Vegetables are high in fiber, vitamins and minerals, which can help regulate blood sugar and GLP-1 levels. Wolfilser – A 2022 study found that eating vegetables before carbs significantly improved glucose and GLP-1 levels in people with type 2 diabetes — especially an hour after eating. America's weight problem Advertisement About one in eight US adults have tried a GLP-1 drug, according to a 2024 KFF poll. Among them, nearly four in 10 say weight loss was the primary reason. Obesity is an epidemic in America, with more than two in five adults and nearly one in five kids and teens classified as obese, per the CDC. The health fallout is huge. Obesity is a risk factor for a wide range of chronic conditions, including heart disease, type 2 diabetes, osteoarthritis, sleep apnea, kidney disease and even several cancers. But it's not just physical. Obesity can take a toll on mental health, with research showing it increases the risk of developing low self-esteem, depression, eating disorders and chronic stress. On top of that, people with obesity often face bias at school and work, taking a serious toll on their quality of life.
